Recent Updates
Recently added Catalysts

VXCO-100

Phase 1

SARS-CoV | Biologics | Infectious Disease |Eli Lilly and Company|Trials Updated: Dec 10, 2024

VXCO-100 development status

Highest phase Phase 1
Registered trials 2 across 1 sponsor since May 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDDMC
Total Trials2
Total Enrollment251

FDA Designations

No designations recorded

VXCO-100 clinical trials

VXCO-100 · 2 trials · 2 indications

Phase 1 2
NCT05938075Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South AfricaSARS-CoV
COMPLETED130 Analytics
NCT05870839Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United StatesSARS-CoV
COMPLETED121 Analytics
PHASE1COMPLETED
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
SARS-CoVUnlock trial analytics
PHASE1COMPLETED
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
SARS-CoVUnlock trial analytics

Study Endpoints

Primary Endpoints

Number and percentage of participants with solicited local adverse events
For 7 days after each product administration
Number and percentage of participants with solicited systemic adverse events
For 7 days after each product administration
Number and percentage of participants with unsolicited and safety laboratory-based adverse events
For 28 days after each product administration
Numbers and percentages of participants with serious adverse events (SAEs) including suspected unexpected serious adverse reactions (SUSARs), medically attended adverse events (MAAEs), and adverse events of special interest (AESIs)
For 364 days after each product administration

Secondary Endpoints

Response rate measured by geometric mean titer of the serum neutralizing antibody (Nab) against the ancestral (Wuhan) strain
At baseline and 21 days after each product administration
Response rate measured by GMT of Nab against selected variants of concern
At baseline and 21 days after each product administration
Numbers and percentages of participants with positive Th1 or Th2 cytokine responses for CD4 and CD8 as measured by multi-parameter intracellular cytokine staining
At baseline and 7 days after each product administration
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
VXC0-100 at Dose level 1EXPERIMENTALParticipants will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 1 on Month 6.
VXC0-100 at Dose level 2EXPERIMENTALParticipants will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 2 on Month 6.
VXC0-100 at Dose level 3EXPERIMENTALParticipants will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection on Day 1 and then an optional boost of VXCO-100 at Dose Level 3 on Month 6.
COVID-19 mRNA vaccineEXPERIMENTALParticipants will receive a COVID-19 mRNA vaccine on Day 1 and then a boost with the same COVID-19 mRNA vaccine at Day 21.
VXCO-100 Group 1EXPERIMENTALParticipants 18-55 years of age will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection
VXCO-100 Group 2EXPERIMENTALParticipants 18-55 years of age will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection
VXCO-100 Group 3EXPERIMENTALParticipants 18-55 years of age will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection
VXCO-100 Group 4EXPERIMENTALParticipants 56+ years of age will receive VXCO-100 at Dose Level 1 via intramuscular (IM) injection
VXCO-100 Group 5EXPERIMENTALParticipants 56+ years of age will receive VXCO-100 at Dose Level 2 via intramuscular (IM) injection
VXCO-100 Group 6EXPERIMENTALParticipants 56+ years of age will receive VXCO-100 at Dose Level 3 via intramuscular (IM) injection

Interventions

NameTypeDescription
VXCO-100BIOLOGICALSterile suspension for injection
COVID-19 mRNA vaccineBIOLOGICALSterile suspension for injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: A participant must meet all the following criteria to be eligible for the study: 1. Adults ages 18 years and older 2. Judged by the investigator to be healthy based on participant-reported medical history, physical examination, vital signs, and laboratory assessment. 3. Able to...

Countries:South AfricaUnited States
Unlock Eligibility Criteria

Frequently asked questions about VXCO-100

What is VXCO-100?

VXCO-100 is an investigational monoclonal antibody developed by Eli Lilly and Company for SARS-CoV. It is being studied as a candidate vaccine against SARS-CoV and SARS-CoV-2. The program is in Phase 1 clinical development, with two completed early-stage trials conducted in healthy adult volunteers.

What is VXCO-100 used for in SARS-CoV?

VXCO-100 is being developed for SARS-CoV, with trial protocols also listing SARS-CoV-2. It is a candidate vaccine intended for use in healthy adults. Both completed Phase 1 studies enrolled healthy volunteers aged 18 years and older, and the program remains investigational rather than approved for any use.

Who makes VXCO-100?

VXCO-100 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the two Phase 1 studies of the candidate vaccine, one run in the United States and one run in the Republic of South Africa.

What phase is VXCO-100 in?

VXCO-100 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no trials are currently active. The program has not been approved by the FDA or any other regulator, so VXCO-100 remains an investigational candidate vaccine for SARS-CoV and SARS-CoV-2.

What clinical trials is VXCO-100 in?

VXCO-100 has been studied in two completed Phase 1 trials. NCT05938075 evaluated the SARS-CoV candidate vaccine in 130 adults in the Republic of South Africa. NCT05870839 evaluated it in 121 healthy adults in the United States. Together the trials enrolled 251 participants, both controlled and randomized, with healthy volunteers only.

How many people were enrolled in VXCO-100 trials?

The two completed Phase 1 trials of VXCO-100 enrolled 251 participants in total. NCT05938075 enrolled 130 adults in the Republic of South Africa, and NCT05870839 enrolled 121 healthy adults in the United States. Both studies were controlled and randomized, enrolled adults 18 years and older, and included both sexes.